Literature DB >> 19797219

Concordance of disease progression in bilateral geographic atrophy due to AMD.

Monika Fleckenstein1, Christine Adrion, Steffen Schmitz-Valckenberg, Arno P Göbel, Almut Bindewald-Wittich, Hendrik P N Scholl, Ulrich Mansmann, Frank G Holz.   

Abstract

PURPOSE: To determine the degree of concordance for progression rate, size of atrophy, and visual acuity in patients with bilateral geographic atrophy (GA) due to age-related macular degeneration (AMD).
METHODS: Analysis was performed in 156 eyes of 78 patients with bilateral GA. Best corrected visual acuity was determined with ETDRS charts. GA was quantified in digital fundus autofluorescence images (excitation, 488 nm; emission, >500 nm) by semiautomated imaging analysis. A linear, two-level, random-effects model was used to assess the natural course of disease. The concordance correlation coefficient (CCC) was calculated to assess the degree of agreement between disease characteristics of the left and right eyes. Bland-Altman plots were applied to compare measurements in the eyes.
RESULTS: CCC between the eyes was 0.310 (95% CI, 0.097-0.495) for visual acuity, 0.706 (95% CI, 0.575-0.801) for GA size, and 0.756 (95% CI, 0.644-0.837) for GA progression rate. Although Bland-Altman plots revealed high concordance for the progression rate, there was considerable discrepancy between both eyes for GA size. [corrected]
CONCLUSIONS: GA progression in bilateral atrophic AMD is a symmetrical process; however, GA size may differ substantially between the eyes. High concordance in intraindividual disease progression in the presence of a high degree of interindividual variability indicates an influence by genetic and/or environmental factors rather than nonspecific ageing changes. The relatively small concordance of GA size in this cohort may indicate asymmetric evolution of the disease in affected individuals. The results may be useful in the design of future clinical trials designed to slow the rate of GA progression (Clinical Trials.gov number, NCT00393692).

Entities:  

Mesh:

Year:  2009        PMID: 19797219     DOI: 10.1167/iovs.09-3547

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  15 in total

1.  New grading criteria allow for earlier detection of geographic atrophy in clinical trials.

Authors:  Hilary Smolen Brader; Gui-Shuang Ying; E Revell Martin; Maureen G Maguire
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-29       Impact factor: 4.799

Review 2.  [Clinical characteristics, progression and risk factors of geographic atrophy].

Authors:  C K Brinkmann; C Adrion; U Mansmann; S Schmitz-Valckenberg; F G Holz
Journal:  Ophthalmologe       Date:  2010-11       Impact factor: 1.059

3.  [Geographic atrophy in AMD].

Authors:  S Schmitz-Valckenberg; F G Holz
Journal:  Ophthalmologe       Date:  2010-11       Impact factor: 1.059

4.  Evolution of Geographic Atrophy in Participants Treated with Ranibizumab for Neovascular Age-related Macular Degeneration.

Authors:  Alisa T Thavikulwat; Naima Jacobs-El; Jane S Kim; Elvira Agrón; Jesia Hasan; Catherine B Meyerle; David Valent; Catherine A Cukras; Henry E Wiley; Wai T Wong; Emily Y Chew
Journal:  Ophthalmol Retina       Date:  2017 Jan-Feb

Review 5.  Fundus autofluorescence imaging in dry AMD: 2014 Jules Gonin lecture of the Retina Research Foundation.

Authors:  Frank G Holz; Julia S Steinberg; Arno Göbel; Monika Fleckenstein; Steffen Schmitz-Valckenberg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-19       Impact factor: 3.117

6.  Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.

Authors:  Wai T Wong; Samuel Dresner; Farzin Forooghian; Tanya Glaser; Lauren Doss; Mei Zhou; Denise Cunningham; Katherine Shimel; Molly Harrington; Keri Hammel; Catherine A Cukras; Frederick L Ferris; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-26       Impact factor: 4.799

7.  Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial.

Authors:  Philip A Petrou; Denise Cunningham; Katherine Shimel; Molly Harrington; Keri Hammel; Catherine A Cukras; Frederick L Ferris; Emily Y Chew; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-18       Impact factor: 4.799

8.  Drusen and RPE atrophy automated quantification by optical coherence tomography in an elderly population.

Authors:  B Diniz; D C Rodger; V R Chavali; T MacKay; S Y Lee; D Stambolian; S V R Sadda
Journal:  Eye (Lond)       Date:  2014-11-07       Impact factor: 3.775

9.  Evaluation of Geographic Atrophy from Color Photographs and Fundus Autofluorescence Images: Age-Related Eye Disease Study 2 Report Number 11.

Authors:  Amitha Domalpally; Ronald Danis; Elvira Agrón; Barbara Blodi; Traci Clemons; Emily Chew
Journal:  Ophthalmology       Date:  2016-07-19       Impact factor: 12.079

10.  Clinical and genetic factors associated with progression of geographic atrophy lesions in age-related macular degeneration.

Authors:  Felix Grassmann; Monika Fleckenstein; Emily Y Chew; Tobias Strunz; Steffen Schmitz-Valckenberg; Arno P Göbel; Michael L Klein; Rinki Ratnapriya; Anand Swaroop; Frank G Holz; Bernhard H F Weber
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.